Open App →
Back to News Feed
Korea Times October 21, 2026 By hansolp@koreatimes.co.kr(KoreaTimes) positive

Capital soundness looms over major insurers' CEO reappointment decisions

SamsungAI / LLM
With the terms of major insurers’ CEOs set to expire early next year, the companies’ capital strength is emerging as a key factor in their chances of reappointment, particularly as new rules requiring insurers to hold stronger financial cushion against losses are set to take effect in 2027, industry officials said Wednesday. The terms of Samsung Life Insurance CEO Hong Won-hak, Samsung Fire & Marine Insurance CEO Lee Mun-hwa, DB Insurance CEO Jeong Jong-pyo and Kyobo Life Insurance co-CEO Cho Dae-kyu are all due to expire in March. All four companies reported higher consolidated net profit in the first half of this year. Samsung Life posted 1.97 trillion won, followed by Samsung Fire & Marine with 1.37 trillion won, DB Insurance with 979.6 billion won and Kyobo Life with 704.8 billion won. But their capital positions showed a more mixed picture. The Korean Insurance Capital Standard (K-ICS) ratio, which measures an insurer’s financial ability to cover its liabilities and risks, rose at Samsung Fire & Marine in the second quarter to 282.8 percent, but fell at the other three — Sa
Read original article ↗

Related Articles

AMEC seeks South Korean foothold through MOCVD trials with SK Keyfoundry, Magnachip

AMEC is seeking an entry into South Korea's power semiconductor market through MOCVD equipment trials with SK Keyfoundry

Digitimes · October 21, 2026

Micron faces potential Taiwan strike, union cites Samsung, SK Hynix profit-sharing benchmark

Micron Technology's Taoyuan union has announced a one-day warning strike for October 22, coinciding with a second round

Digitimes · October 21, 2026

Sony bets on cinema-grade audio, mobile accessories to counter smartphone sales slump

Sony's smartphone business continues to struggle amid fierce competition from Apple, Samsung Electronics, and Chinese ri

Digitimes · October 21, 2026

Samsung Bioepis wins FDA Fast Track for 1st anticancer drug candidate

Samsung Bioepis has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SBE303, an anti

Korea Times · October 21, 2026